Analysts Expect VIVUS, Inc. (VVUS) Will Post Earnings of -$0.11 Per Share

Equities analysts expect VIVUS, Inc. (NASDAQ:VVUS) to announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.13) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The firm is scheduled to issue its next earnings report on Thursday, August 2nd.

According to Zacks, analysts expect that VIVUS will report full-year earnings of ($0.43) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($0.57) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover VIVUS.

VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. VIVUS had a negative net margin of 79.80% and a negative return on equity of 843.43%. The business had revenue of $11.90 million during the quarter.

Several research firms have weighed in on VVUS. ValuEngine raised shares of VIVUS from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research raised shares of VIVUS from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Thursday, May 31st.

VVUS opened at $0.85 on Thursday. VIVUS has a 1-year low of $0.33 and a 1-year high of $1.32. The company has a quick ratio of 7.94, a current ratio of 8.67 and a debt-to-equity ratio of -12.06. The firm has a market capitalization of $76.22 million, a price-to-earnings ratio of -2.94 and a beta of 0.83.

In related news, CEO John P. Amos purchased 540,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was purchased at an average cost of $0.56 per share, with a total value of $302,400.00. Following the completion of the purchase, the chief executive officer now owns 810,000 shares in the company, valued at approximately $453,600. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO John P. Amos purchased 270,000 shares of the firm’s stock in a transaction on Friday, May 11th. The stock was bought at an average cost of $0.52 per share, with a total value of $140,400.00. Following the completion of the purchase, the chief executive officer now owns 270,000 shares of the company’s stock, valued at approximately $140,400. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 1,820,000 shares of company stock valued at $1,090,500. Insiders own 4.40% of the company’s stock.

An institutional investor recently raised its position in VIVUS stock. Creative Planning lifted its holdings in shares of VIVUS, Inc. (NASDAQ:VVUS) by 1,691.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 366,706 shares of the biopharmaceutical company’s stock after acquiring an additional 346,235 shares during the period. Creative Planning owned approximately 0.35% of VIVUS worth $184,000 at the end of the most recent reporting period. 21.15% of the stock is owned by hedge funds and other institutional investors.

VIVUS Company Profile

VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

Get a free copy of the Zacks research report on VIVUS (VVUS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.

Leave a Reply